• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells
AbstractLipidoid nanoparticles (LNPs) are the delivery platform in Onpattro, the first FDA-approved siRNA drug. LNPs are also the carriers in the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. While these applications have demonstrated that LNPs effectively deliver nucleic acids to hepatic and muscle cells, it is unclear if LNPs could be used for delivery of siRNA to neural cells, which are notoriously challenging delivery targets. Therefore, the purpose of this study was to determine if LNPs could efficiently deliver siRNA to neurons. Because of their potential  delivery utility in either applications for the centra...
Source: The AAPS Journal - December 6, 2021 Category: Drugs & Pharmacology Source Type: research

siRNA as a potential therapy for COVID-19
Curr Drug Deliv. 2021 Aug 5. doi: 10.2174/1567201818666210805145320. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) is a highly contagious virus causing COVID-19 disease that severely impacted the world health, education, and economy systems in 2020. The numbers of infection cases and reported deaths are still increasing with no specific treatment identified yet to halt this pandemic. Currently, several proposed treatments are under preclinical and clinical investigations now, alongside the race to vaccinate to as much individuals as possible. The genome of SARS-CoV2 share similar...
Source: Current Drug Delivery - August 6, 2021 Category: Drugs & Pharmacology Authors: Ahmad Aljaberi Eman M Migdadi Khalid M Abu Khadra Mahmoud Abu Samak Iman A Basheti Nizar Al-Zoubi Source Type: research

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Drug Metab Pharmacokinet. 2021 Oct 10;41:100424. doi: 10.1016/j.dmpk.2021.100424. Online ahead of print.ABSTRACTNucleic acid therapeutics are developing into precise medicines that can manipulate specific genes. However, the development of safe and effective delivery system for the target cells has remained a challenge. Lipid nanoparticles (LNPs) have provided a revolutionary delivery system that can ensure multiple clinical translation of RNA-based candidates. In 2018, Patisiran (Onpattro) was first approved as an LNP-based siRNA drug. In 2020, during the coronavirus disease 2019 (COVID-19) outbreak, LNPs have enabled the...
Source: Drug Metabolism and Pharmacokinetics - November 10, 2021 Category: Drugs & Pharmacology Authors: Yuta Suzuki Hiroshi Ishihara Source Type: research

Pages: 1  2  3  4